STOCK TITAN

Gain Therapeutics, Inc. - GANX STOCK NEWS

Welcome to our dedicated page for Gain Therapeutics news (Ticker: GANX), a resource for investors and traders seeking the latest updates and insights on Gain Therapeutics stock.

Gain Therapeutics, Inc. (NASDAQ: GANX) is a clinical-stage biotech company pioneering novel small molecule therapies for neurodegenerative diseases and rare genetic disorders through its proprietary computational drug discovery platform. This page serves as the definitive source for verified updates on clinical trials, research breakthroughs, and corporate developments.

Investors and researchers will find timely updates on the company’s lead candidate GT-02287 for Parkinson’s disease, along with pipeline progress across lysosomal storage disorders and oncology targets. Our curated news collection includes earnings reports, partnership announcements, and scientific presentations – all essential for understanding GANX’s position in the competitive biopharmaceutical landscape.

Key updates cover three critical areas: clinical trial milestones for brain-penetrant therapies, advancements in AI-driven target identification via the Magellan platform, and strategic collaborations accelerating therapeutic development. Bookmark this page to track how GANX’s focus on allosteric modulation could reshape treatment paradigms.

Rhea-AI Summary
Gain Therapeutics, Inc. (GANX) announces the initiation of the Multiple Ascending Dose (MAD) part of the Phase 1 clinical trial of GT-02287 for GBA1 Parkinson’s disease. The trial remains on track with positive safety and tolerability profiles observed in earlier cohorts. GT-02287 has shown promising preclinical data in restoring motor function and reducing neurodegeneration biomarkers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.89%
Tags
-
Rhea-AI Summary
Gain Therapeutics, Inc. (GANX) to hold a 2024 Research & Development update on February 22, 2024, focusing on GT-02287 in vivo data for Parkinson's Disease. Key Opinion Leaders to provide insights on unmet medical needs and therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.88%
Tags
none
-
Rhea-AI Summary
Gain Therapeutics, Inc. (Nasdaq: GANX) presents preclinical data at the 20th WORLDSymposium™, demonstrating the neuroprotective effects and motor function restoration of its clinical-stage GCase regulator GT-02287 in Parkinson's disease models. The data show a progressive reversal of motor deficit and a reduction of the neurodegeneration biomarker NfL to the level of the control arm. The company is currently conducting a Phase 1 clinical trial of GT-02287 in healthy adults and plans to commence treatment of patients in an extension of that clinical trial in Q3 of this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
none
Rhea-AI Summary
Gain Therapeutics, Inc. releases a letter to stockholders from its CEO, Matthias Alder, highlighting the progress of the company in 2023 and its strategy for 2024. They focus on the development of their lead drug candidate for Parkinson's disease, GT-02287, and present preclinical data supporting its potential. Additionally, they discuss the upgrade of their computational drug discovery platform, Magellan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Gain Therapeutics, Inc. (Nasdaq: GANX) announced new data of GT-02287 in preclinical models of Parkinson’s disease accepted for a platform presentation at the 20th Annual WORLDSymposium™. The presentation will focus on GT-02287, a clinical stage GCase enhancer, displaying neuroprotection and restoring motor function in preclinical models of Parkinson’s disease following delayed administration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.03%
Tags
none
-
Rhea-AI Summary
Gain Therapeutics, Inc. (Nasdaq: GANX) announced CEO Matthias Alder's participation in a fireside chat with John Vandermosten, CFA, Senior Analyst for Zacks Small-Cap Research on December 5, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.82%
Tags
conferences
Rhea-AI Summary
Gain Therapeutics, Inc. (Nasdaq: GANX) announced the publication of preclinical data identifying a novel class of small molecule allosteric regulators with therapeutic potential for galactosidase beta 1 (GLB1)-related lysosomal storage disorders, including GM1 gangliosidosis. The study was published in PLOS ONE and demonstrated the potential of allosteric modulators as a therapeutic option for hard-to-treat genetic diseases where there are no effective approaches for disease modification.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.8%
Tags
-
Rhea-AI Summary
Gain Therapeutics, Inc. (Nasdaq: GANX) announced that CEO Matthias Alder will participate in a panel at the AI Driven Drug Discovery Summit on December 6, 2023. The event will focus on collaboration in AI-driven drug discovery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
conferences AI
-
Rhea-AI Summary
Gain Therapeutics, Inc. (Gain) (Nasdaq: GANX) closed an underwritten public offering of 2,545,000 shares of common stock and warrants to purchase up to 1,272,500 shares at a combined public offering price of $2.005 per share and accompanying warrant. In a private placement, Gain issued 2,500,088 shares of common stock and warrants to purchase up to 2,500,088 shares at an offering price of $2.00 per share. The gross proceeds from the offerings were approximately $10.1 million, excluding underwriting and placement agent discounts and commissions and other offering-related expenses. Gain intends to use the net proceeds for the development of its lead product candidate GT-02287 for the treatment of neurodegenerative diseases and for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.37%
Tags
Rhea-AI Summary
Gain Therapeutics, Inc. (GANX) announced the pricing of an underwritten public offering of 2,213,044 shares of its common stock and warrants to purchase up to an aggregate of 1,106,522 shares of its common stock at a combined public offering price of $2.005 per share and accompanying warrant. The public offering price for each set of two shares of common stock and accompanying warrant to purchase one share of common stock is $4.01 per set of securities, yielding an effective price of $2.00 per share and $0.01 per warrant. The warrants are being sold at the rate of one warrant for every two shares of common stock. The warrants will have an exercise price of $2.75 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance. In connection with the offering, Gain has granted the underwriters a 30-day option to purchase up to an additional 15% of shares of common stock and/or warrants to purchase shares of common stock at the public offering price, less underwriting discounts and commissions. In a private placement to be completed concurrently with the completion of the public offering, Gain will issue to an accredited investor an aggregate of 2,500,088 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,500,088 shares of common stock. The offering price per share and accompanying warrant sold in the private placement is $2.00. The warrants issued in the private placement will be exercisable at an exercise price of $2.75 per share, will be exercisable beginning six months after issuance and will expire five years from the date of issuance. Newbridge Securities Corporation is acting as the sole book-running manager for the public offering and as placement agent for the private placement. Allele Capital Partners, LLC is acting as Financial Advisor to Gain. Gain expects to receive aggregate gross proceeds from the public and private offering, excluding the exercise of the underwriters’ option, if any, of approximately $9.4 million, excluding underwriting and placement agent discounts and commissions and other offering-related expenses. The offerings are expected to close on or before November 28, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.9%
Tags
Gain Therapeutics, Inc.

Nasdaq:GANX

GANX Rankings

GANX Stock Data

50.02M
26.49M
5.01%
7.64%
1.32%
Biotechnology
Pharmaceutical Preparations
Link
United States
BETHESDA